Directional bias · probability of rising · expected price and likely range (68%)
| Horizon | Bias | Prob. up | Expected price | 68% range |
|---|---|---|---|---|
| 1 day | Bullish | 56% | $790.37 -0.0% | $776.10 – $804.90 |
| 3 days | Bullish | 56% | $789.64 -0.1% | $765.11 – $814.95 |
| 1 week | Bullish | 56% | $788.90 -0.2% | $757.41 – $821.70 |
| 15 days | Bullish | 56% | $787.06 -0.5% | $743.00 – $833.74 |
| 1 month | Bullish | 55% | $783.04 -1.0% | $720.32 – $851.22 |
| 3 months | Bullish | 52% | $767.86 -2.9% | $664.48 – $887.32 |
Recent momentum: +0.8% over 20 days · +21.3% over 60 days. The further out the horizon, the wider and more uncertain the forecast.
The public money behind this company — the "Follow the Contract" pattern.
Inmazeb ebola therapeutics
💡 Worth 0.34% of the company's market value. Firm money at signing: $278 M. Stock since the announcement: +0.3%.
The verdict combines trend (20/50/200 moving averages), momentum (RSI, MACD), mean reversion (Bollinger Bands), conviction (volume) and historical drift, weighted differently for each horizon. Uncertainty is modeled with a lognormal probability cone (geometric Brownian motion). This is statistical analysis, not a crystal ball.
Other stocks Faro watches